Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital

Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success

Leerink Partners analyst Geoffrey Porges reduced Aducanumab probability of success and cut his price target on Biogen (NASDAQ: BIIB) price target of $355.00 (from $365.00) after Lilly announced on Wednesday that the EXPEDITION 3 study of solanezumab (sola) in mild Alzheimer's patients did not meet its primary or secondary... More

Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird

Baird analyst Brian Skorney weighed in on Biogen (NASDAQ: BIIB), saying Eli Lilly's Solanezumab failure is a negative for the company.,

Skorney commented, "Lilly's registrational EXPEDITION 3 trial for solanezumab in mild Alzheimer's patients failed. Though some secondary endpoints favored sola, Lilly's admission that... More

Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness

Mizuho analyst Salim Syed weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly announced this morning that its Alzheimer's drug, Solanezumab Phase 3 study has failed and it will not pursue approval which has implications to Biogen's Aducanumab.

Syed commented, "While we are... More

Sola Failures Appears 'Near-Perfect' for Biogen (BIIB) - Stifel

Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) Eli Lilly's Solanezumab did not meet its primary endpoint in the EXPEDITION3 clinical trial. Solanezumab's near-miss is near-Perfect for Biogen, Shrader said.

Shrader commented, "Solanezumab did not meet its primary endpoint in... More

Forward Pharma (FWP): Reiterating Buy Ahead Of Next Week's Litigation - Leerink

Leerink Partners analyst, Jason Gerberry, reiterated his Outperform rating on shares of Forward Pharma (NASDAQ: FWP) ahead of the interference oral arguments. The analyst is modeling 65% odds to FWP prevailing in its patent interference dispute with Biogen (NASDAQ:... More

Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink

Leerink Partners analyst Geoffrey Porges weighed in on Biogen (NASDAQ: BIIB) after Eli Lilly (NYSE: LLY) announced that the solanezumab (sola) phase III trial in patients with mild Alzheimers disease failed to meet statistical significance on the primary endpoint and only... More

Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure

Biogen (NASDAQ: BIIB) is trading down 1% in pre-open trade following news Eli Lilly and Company (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).